[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"other-protocol-specified-criteria\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:other-protocol-specified-criteria":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100525931","phase-1-phase-i-study-of-jyp0322-in-ros1-fusion-positive-solid-tumors-100525931",false,"NCT06128148","Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors","A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of JYP0322 in Patients With Solid Tumors","JYP0322","Key Inclusion Criteria\n\n* Adult patients age 18 years or older.\n* Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors that have a ROS1 molecular fusion.\n* Measurable disease according to RECIST version 1.1\n* Life expectancy of at least 3 months\n* Other protocol specified criteria\n\nKey Exclusion Criteria:\n\n* Current participation in another therapeutic clinical trial.\n* Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.\n* A history of severe allergies, or a history of severe allergy, hypersensitivity or other hypersensitivity to any active or inactive ingredient of the study drug.\n* Known active infections (bacterial, viral including HIV positivity).\n* Other protocol specified criteria","ALL","18 Years",{"count":20,"type":21},101,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced\u002Fmetastatic solid tumors .",[27,28,29,30],"Protein Kinase Inhibitors","Other Protocol Specified Criteria","Lung Neoplasms","Brain Neoplasms",[32,33,34,35],"ROS1 Fusions","ROS1 Gene Rearrangements","Primary brain tumors","ROS1","RECRUITING","2025-07-09",{"date":39,"type":40},"2025-07-14","ACTUAL",{"date":42,"type":40},"2022-05-04",{"date":44,"type":21},"2027-12-30",{"name":46,"class":47},"Guangzhou JOYO Pharma Co., Ltd","INDUSTRY"]